NOT KNOWN FACTS ABOUT ZANUBRUTINIB

) associated with primary ibrutinib resistance in MCL cell strains. This observation was even more confirmed in one hundred sixty five primary MCL samples where by fifteen% of the tumors that didn't respond to ibrutinib treatment experienced mutations in TRAF3In the meantime, to make certain continued support, we have been exhibiting the location d